Alpha-1 antitrypsin deficiency (AATD)

What changes during this transition

AATD is a genetic disease — autosomal codominant SERPINA1 mutations (PiZZ severe, PiSZ intermediate, PiMZ carriers) producing misfolded Z polymer that fails to leave hepatocytes (causing liver disease from polymer accumulation) AND fails to reach the lung in sufficient quantity to inhibit neutrophil elastase (causing panacinar emphysema, classically lower-lobe). Extrapulmonary manifestations include panniculitis and ANCA-associated vasculitis. The two-tissue (liver + lung) split is editorially load-bearing: the hepatic axis is misfolding-driven (polymer accumulating IN the hepatocyte) while the pulmonary axis is deficiency-driven (insufficient AAT reaching the lung). These require different therapeutic strategies. Standard-of-care backbone: **Smoking cessation** is the only intervention that modifies the natural history of pulmonary AATD. A PiZZ patient who never smokes may never develop clinically significant emphysema; a PiZZ patient who smokes loses ~2 decades of life expectancy. This is the COPD-framing parallel — every other intervention is secondary to this. **Augmentation therapy** (Prolastin-C, Zemaira, Aralast NP, Glassia) — weekly IV infusion of pooled-plasma alpha-1 antitrypsin, FDA-approved for PiZZ + severe deficiency (level <11 µM) + emphysema. RAPID and RAPID-OLE trials demonstrated preservation of CT lung-density decline. Does NOT address the liver disease (the liver problem is the misfolded protein accumulating IN the hepatocyte, not deficiency at the destination tissue). **Fazirsiran** (Takeda/Arrowhead, formerly TAK-999 / ARO-AAT) — hepatocyte-targeted siRNA, Phase 3 SEQUOIA trial for AATD liver disease. Reduces hepatic Z-AAT polymer production. First disease-modifying therapy for the hepatic axis. **Beam Therapeutics base-editing program** (BEAM-302) — Phase 1/2 in-vivo CRISPR base-editor correcting the E342K mutation directly. VX-864 (Vertex small-molecule corrector) was discontinued; VX-634 is the follow-on candidate. These are the curative-intent programs. **AlphaNet** — patient-services organization administering augmentation therapy support and the AlphaNet Disease Management & Prevention Program. **Genetic testing + family screening** — ATS/ERS 2003 + 2024 update guidelines recommend testing every COPD patient + every first-degree relative of an index case. Underdiagnosis is the central public-health problem in AATD. COPD background therapy applies: LABA/LAMA, ICS in eosinophilic phenotype, ensifentrine for moderate-severe disease (FDA June 2024), dupilumab for the eosinophilic/type-2-high subset (FDA September 2024). Liver transplant for end-stage cirrhosis; lung transplant for end-stage emphysema. Carbamazepine and rapamycin have been studied in AATD liver disease specifically as autophagy-targeted strategies (carbamazepine reaching Phase 2/3 at NIH for severe pediatric liver disease). Where Juno's library fits — narrowly and with deliberate non-elevation. None of the candidate peptides (BPC-157, TB-500, NMN, SS-31, Thymosin alpha-1) addresses SERPINA1 biology. AATD has augmentation therapy at the protein level, siRNA at the hepatic-source level, and base editing at the genetic level — three modalities already operating on the actual pathway. BPC-157's generic 'liver and lung healing' framing doesn't translate to misfolding-driven hereditary hepatopathy. TB-500's 'lung tissue regeneration' angle conflicts with the reality that no intervention reverses established emphysematous tissue loss (lung transplant is the only 'replacement' option). NMN's 'NAD+ supports autophagy' framing skips the unvalidated steps; carbamazepine and rapamycin are the actually-studied autophagy-targeted agents in AATD liver disease. SS-31 / elamipretide has the most coherent mechanism (Z-polymer accumulation does drive hepatocyte mitochondrial dysfunction) but the Forzinity Barth syndrome FDA approval (March 2025) does NOT propagate to AATD per Rule 6. Thymosin alpha-1's hepatitis-B and hepatitis-C indications do NOT propagate to misfolding-driven AATD liver disease — the mechanisms are entirely different. Surfacing peptides as discovery cards on a `/guides/by-life-stage/a1at-deficiency` page would falsely imply they belong in an AATD protocol. The honest editorial frame: pulmonology + hepatology specialist coordination (rheumatology if ANCA vasculitis is a manifestation), augmentation therapy access through AlphaNet, fazirsiran SEQUOIA trial enrollment for the hepatic axis, Beam Therapeutics BEAM-302 trial consideration for the curative-intent program, smoking cessation as the only pulmonary-disease-modifying intervention, and family screening per ATS/ERS 2024 update drive outcomes.